FEMTELLE® is a clinically validated prognosis test in primary breast cancer. It allows a quantitative determination of the two prognostic factors uPA (urokinase-type plasminogen activator) and its inhibitor PAI-1 in tumor tissue. The test helps to determine risk of disease recurrence and predicts chemotherapy benefit in breast cancer patients.

In node-negative breast cancer risk assessment is essential for adjuvant therapy decisions. FEMTELLE® provides reliable information to physicians and patients for a risk adapted individualized therapy decision.

Click here for more information about FEMTELLE®

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.